Step 1 topics → Cardiovascular → Heart Failure Pharmacotherapy

Heart Failure Pharmacotherapy

USMLE Step 1 trap: Confuses the ARNI washout rationale (angioedema via dual bradykinin blockade) with a hemodynamic concern. The washout is required because sacubitril inhibits neprilysin (which degrades bradykinin), and concurrent ACEi also prevents bradykinin breakdown, causing dangerous bradykinin accumulation and angioedema risk.

Heart failure pharmacotherapy — specifically guideline-directed medical therapy (GDMT) for HFrEF — is one of the highest-yield cardiology topics on USMLE Step 1, and students consistently reach for digoxin when the question asks for the fourth GDMT pillar, which is now SGLT2 inhibitors. The exam tests this from multiple angles: pure recall of drug classes, mechanism questions that require you to explain *why* a drug works or why it's contraindicated, and clinical vignettes where you have to select the correct agent for a specific patient population. The core framework is the four pillars of GDMT, and if you have that locked down cold, you can answer most questions correctly.

The tricky part is that this topic has several landmines. The biggest one is that digoxin is *not* a pillar of modern GDMT — students who learned older guidelines or studied from outdated sources will instinctively reach for digoxin when they see symptomatic HFrEF, especially in Black patients. That's exactly the wrong answer. SGLT2 inhibitors replaced digoxin as the fourth pillar, and USMLE Step 1 is now testing whether you know this. The hydralazine/isosorbide dinitrate combination also trips people up: it's specific to a defined population (self-identified Black patients with HFrEF on optimized GDMT, from the A-HeFT trial), not a generic substitute for ACEi in CKD.

The ARNI mechanism question is another classic trap. Most students know the 36-hour ACEi washout before starting sacubitril/valsartan, but they think it's about blood pressure. It's not — it's about angioedema. Sacubitril inhibits neprilysin, which normally degrades bradykinin. ACEi *also* prevents bradykinin breakdown. Run both simultaneously and you get dangerous bradykinin accumulation. USMLE Step 1 will give you a stem describing angioedema or ask you to explain the washout rationale, and hypotension is the wrong answer.

From real student decks
89%have cards covering this topic
65%have mature cards

Common misconceptions

Common mistake
Wrong: The 36-hour ACEi washout before starting ARNI is needed to prevent hypotension from dual renin-angiotensin blockade.
Right: The washout is required because sacubitril inhibits neprilysin (which degrades bradykinin), and concurrent ACEi also prevents bradykinin breakdown, causing dangerous bradykinin accumulation and angioedema risk.
The washout period is not about avoiding double renin-angiotensin blockade or hypotension — valsartan already handles that side of the equation. The danger is bradykinin accumulation: neprilysin normally degrades bradykinin, so sacubitril blocking neprilysin raises bradykinin levels. If you also have an ACEi on board (which blocks bradykinin degradation via a different pathway), bradykinin stacks to dangerous levels, causing angioedema. This is the same mechanism behind ACEi-induced angioedema, just amplified.
Common mistake
Wrong: Digoxin provides a mortality benefit in HFrEF and select it for symptomatic Black patients on full GDMT.
Right: Digoxin reduces hospitalizations and symptoms but has no mortality benefit; hydralazine/isosorbide dinitrate (A-HeFT trial) provides mortality benefit specifically in self-identified Black patients with HFrEF symptomatic on standard GDMT.
Digoxin is a symptomatic agent — it improves exercise tolerance and reduces hospitalizations, but multiple trials have shown zero mortality benefit. When a HFrEF patient is Black and symptomatic on optimized GDMT, the A-HeFT trial showed that adding hydralazine/isosorbide dinitrate reduces mortality by about 43%. Digoxin has no role in that mortality calculation. On the exam, if the question asks what to *add for survival benefit* in this population, hydralazine/nitrates is the answer, not digoxin.
Common mistake
Wrong: Hydralazine/nitrate combination is indicated primarily for patients with CKD who cannot tolerate ACEi/ARB.
Right: Hydralazine/isosorbide dinitrate has a proven mortality benefit specifically in self-identified Black patients with HFrEF who remain symptomatic on optimized GDMT, per the A-HeFT trial.
Hydralazine/isosorbide dinitrate is sometimes used off-label when patients cannot tolerate ACEi/ARB (e.g., severe CKD or bilateral renal artery stenosis), but that's not its evidence-based indication with mortality data. The A-HeFT trial specifically enrolled self-identified Black patients with HFrEF who were already on standard therapy and still symptomatic — and found a survival benefit in that group. This is a population-specific mortality indication, not a CKD workaround. The exam will test whether you know the correct population.
Common mistake
Wrong: The four pillars of HFrEF GDMT are ACEi/ARB/ARNI, beta-blocker, MRA, and digoxin.
Right: The four pillars of HFrEF GDMT are ACEi/ARB/ARNI, beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor; digoxin is not a GDMT pillar.
Digoxin was historically used in HFrEF but was never shown to reduce mortality and carries a narrow therapeutic index with significant toxicity risk. SGLT2 inhibitors (empagliflozin, dapagliflozin) have now demonstrated robust mortality and hospitalization benefits in HFrEF regardless of diabetes status, making them the fourth pillar of modern GDMT. If you see a question listing the four pillars and one option includes digoxin in place of SGLT2i, that option is wrong — this is one of the clearest updates from older to newer guidelines that USMLE Step 1 is actively testing.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know all four pillars of HFrEF GDMT by name and class: ACEi/ARB/ARNI, beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor — and know that digoxin is NOT one of them.
  2. Explain the mechanism behind the 36-hour ACEi washout requirement before starting ARNI (sacubitril/valsartan): it prevents angioedema from dual bradykinin accumulation, not hemodynamic instability.
  3. Identify the correct indication for hydralazine/isosorbide dinitrate in HFrEF: mortality benefit in self-identified Black patients who remain symptomatic on optimized GDMT (A-HeFT trial), not as a CKD-related ACEi substitute.

Can you avoid these mistakes?

A 58-year-old man with HFrEF (EF 30%) is currently on lisinopril, carvedilol, and spironolactone. His symptoms are well-controlled. What is the fourth GDMT agent you should consider adding, and what class does it belong to?
A patient with HFrEF is being switched from lisinopril to sacubitril/valsartan (ARNI). Why must you wait 36 hours after stopping the ACEi before starting the ARNI — and what serious adverse event are you trying to prevent?
A 65-year-old self-identified Black woman with HFrEF remains NYHA class III despite being on maximally tolerated ACEi, beta-blocker, MRA, and SGLT2i. Which medication has a proven mortality benefit specifically for this patient, and what trial supports it?
Which of the following has a mortality benefit in HFrEF: digoxin, hydralazine/isosorbide dinitrate, or both? In which specific patient population does the mortality benefit apply for the correct answer?

Related topics

Heart Failure Types (HFrEF / HFpEF / Right-Sided) Heart Development and Looping Cardiac Septation Fetal Circulation and Transition Coronary Arteries and Territories

See how your Anki deck covers this topic.

Upload your deck for a free audit →